Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of flexible-dose fesoterodine in elderly patients with overactive bladder
2010-018254-12Phase 4Completed
- Sponsor
- Pfizer
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fesoterodine in overactive bladder (OAB), sponsored by Pfizer. Primary endpoint: Mean number of micturition-related urgency episodes per 24 hours at end of treatment. Started Feb 2010; status: completed.
02
Drugs
fesoterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2010-018254-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018254-12.